Sitka Biopharma Inc. is pleased to announce that Dr. Kristine Swiderek and Dr. Jack Geltosky have joined its Board of
Quark Venture releases final tranche of funding
Quark Venture’s early investment in Sitka Biopharma helps the Vancouver-based company advance to clinical trials. We are pleased to announce
New Bladder Cancer Therapy to Start Clinical Trials
June 26, 2017 – Vancouver, BC and London, UK: An experimental treatment for bladder cancer will move into an early
Sitka Biopharma is Ready to Rocket!
On March 3, 2017 Rocket Builders announced its 15th annual “Ready to Rocket” lists. These lists profile British Columbia technology
Quark Venture Makes Significant Seed Investment in CDRD-UBC Spin-off, Sitka Biopharma
Vancouver, Canada – April 13, 2016: Sitka Biopharma is pleased to announce that Quark Venture has made a significant seed
Exploiting the potential of nanotechnology in bladder cancer treatment
Learn more about Sitka Biopharma’s unique approach to bladder cancer in International Innovation! Drs Helen Burt, Michael Parr, Richard Liggins and
CDRD Ventures Inc. of Vancouver, Canada Launches New Spin-off, Sitka Biopharma
Vancouver, Canada – December 3, 2013: CDRD Ventures Inc. (CVI), the commercialization vehicle of The Centre for Drug Research and
